29th July 2022 – Blueberry Therapeutics issued a press release, which is summarized as follows:
Blueberry Therapeutics are pleased to announce that recruitment into the Phase 2b European trial of BB2603 for fungal nail infection is now complete.
This trial (BBTAF202) assesses the efficacy and safety of different doses of BB2603, a new topical anti-fungal formulation, in patients with fungal nail infection (onychomycosis). Data from the primary endpoint (an early response assessment at 16 weeks) are expected in Q1 2023, with final results to follow for the 52-week endpoints.
Original Link: https://www.blueberrytherapeutics.com/blueberry-therapeutics-announce-recruitment-complet/